{
  "id": "6025a1e91cb411341a0000b4",
  "type": "list",
  "question": "List 3 conventional synthetic DMARDs.",
  "ideal_answer": "Three conventional synthetic (cs) DMARDs include methotrexate (MTX), leflunomide, and sulfasalazine.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/29231235",
    "http://www.ncbi.nlm.nih.gov/pubmed/24072562",
    "http://www.ncbi.nlm.nih.gov/pubmed/31969328"
  ],
  "snippets": [
    {
      "text": "The task force agreed on 5 overarching principles and 12 recommendations concerning use of conventional synthetic (cs) DMARDs (methotrexate (MTX), leflunomide, sulfasalazine); glucocorticoids (GCs); biological (b) DMARDs (tumour necrosis factor inhibitors (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab), abatacept, rituximab, tocilizumab, sarilumab and biosimilar (bs) DMARDs) and targeted synthetic (ts) DMARDs (the Janus kinase (JAK) inhibitors tofacitinib, baricitinib, filgotinib, upadacitinib). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31969328",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "RESULTS: The task force agreed on 5 overarching principles and 12 recommendations concerning use of conventional synthetic (cs) DMARDs (methotrexate (MTX), leflunomide, sulfasalazine); glucocorticoids (GCs); biological (b) DMARDs (tumour necrosis factor inhibitors (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab), abatacept, rituximab, tocilizumab, sarilumab and biosimilar (bs) DMARDs) and targeted synthetic (ts) DMARDs (the Janus kinase (JAK) inhibitors tofacitinib, baricitinib, filgotinib, upadacitinib).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31969328",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Conventional synthetic DMARDs such as methotrexate, sulfasalazine, leflunomide, hydroxychloroquine appear to be safe during the perioperative period.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29231235",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "tsDMARDs would then constitute only those that were specifically developed to target a particular molecular structure (such as tofacitinib, fostamatinib, baricitinib or apremilast, or agents not focused primarily on rheumatic diseases, such as imatinib or ibrutinib), while csDMARDs would comprise the traditional drugs (such as methotrexate, sulfasalazine, leflunomide, hydroxychloroquine, gold salts and others).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24072562",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "methotrexate, leflunomide, sulfasalazine"
}